Vera Therapeutics Adds Ex-Royalty Pharma EVP Christopher Hite to Board Ahead of Atacicept Launch
Vera Therapeutics appointed Christopher Hite to its Board as an independent director, bringing over 25 years of biopharmaceutical corporate and financial strategy experience from roles at Royalty Pharma, Citi and Lehman Brothers. His appointment coincides with preparations for the potential launch of atacicept, a dual BAFF/APRIL inhibitor targeting IgA nephropathy.
1. Board Appointment
On March 5, 2026, Vera Therapeutics announced the appointment of Christopher Hite as an independent director, expanding its Board of Directors with a seasoned biopharma executive.
2. Executive Background
Hite has over 25 years of strategic and financial leadership in the biopharmaceutical sector, currently serving as Executive Vice President and Vice Chairman at Royalty Pharma, and previously holding vice chair and global healthcare investment banking roles at Citi and Lehman Brothers.
3. Strategic Implications
Hite’s financial and corporate strategy expertise is expected to strengthen governance and support capital planning as Vera advances its late-stage development programs and prepares for commercialization milestones.
4. Atacicept Development Pipeline
Vera’s lead candidate, atacicept – a first-in-class, self-administered dual BAFF/APRIL inhibitor for IgA nephropathy – is slated for potential launch later this year, with additional indications and next-generation fusion protein VT-109 progressing in the pipeline.